Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHC NASDAQ:NGNE NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHCAcadia Healthcare$34.50+2.6%$26.78$11.43▼$34.74$3.09B0.643.44 million shs2.75 million shsNGNENeurogene$37.31+2.2%$31.32$15.93▼$43.66$576.77M1.68293,275 shs473,344 shsTSHATaysha Gene Therapies$5.96-0.2%$6.06$2.34▼$7.30$1.72B1.174.03 million shs2.85 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHCAcadia Healthcare+2.65%+10.29%+46.81%+27.78%+52.12%NGNENeurogene+2.22%-5.85%+21.18%+33.97%+65.53%TSHATaysha Gene Therapies-0.17%-5.99%-3.72%-7.31%+134.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHCAcadia Healthcare$34.50+2.6%$26.78$11.43▼$34.74$3.09B0.643.44 million shs2.75 million shsNGNENeurogene$37.31+2.2%$31.32$15.93▼$43.66$576.77M1.68293,275 shs473,344 shsTSHATaysha Gene Therapies$5.96-0.2%$6.06$2.34▼$7.30$1.72B1.174.03 million shs2.85 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHCAcadia Healthcare+2.65%+10.29%+46.81%+27.78%+52.12%NGNENeurogene+2.22%-5.85%+21.18%+33.97%+65.53%TSHATaysha Gene Therapies-0.17%-5.99%-3.72%-7.31%+134.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHCAcadia Healthcare 2.47Hold$28.69-16.83% DownsideNGNENeurogene 3.00Buy$84.83127.37% UpsideTSHATaysha Gene Therapies 3.00Buy$12.62111.67% UpsideCurrent Analyst Ratings BreakdownLatest ACHC, NGNE, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026ACHCAcadia Healthcare KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $40.007/14/2026ACHCAcadia Healthcare TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $36.007/9/2026ACHCAcadia Healthcare UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $39.007/2/2026TSHATaysha Gene Therapies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$11.006/30/2026TSHATaysha Gene Therapies Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/30/2026TSHATaysha Gene Therapies Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.006/24/2026TSHATaysha Gene Therapies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026TSHATaysha Gene Therapies Pivotal ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$14.006/23/2026TSHATaysha Gene Therapies BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $14.006/23/2026TSHATaysha Gene Therapies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/23/2026TSHATaysha Gene Therapies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$8.00 ➝ $11.00(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHCAcadia Healthcare$3.37B0.94$4.19 per share8.23$21.12 per share1.63NGNENeurogene$930K633.87N/AN/A$17.10 per share2.18TSHATaysha Gene Therapies$9.77M175.30N/AN/A$0.90 per share6.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHCAcadia Healthcare-$1.10B-$12.24N/A20.0611.21-32.84%7.09%3.01%7/28/2026 (Confirmed)NGNENeurogene-$90.35M-$4.55N/AN/AN/AN/A-37.88%-34.70%8/10/2026 (Estimated)TSHATaysha Gene Therapies-$109M-$0.38N/AN/AN/AN/A-56.07%-40.16%8/11/2026 (Estimated)Latest ACHC, NGNE, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026TSHATaysha Gene Therapies-$0.11N/AN/AN/A$0.62 millionN/A8/10/2026Q2 2026NGNENeurogene-$1.40N/AN/AN/AN/AN/A7/28/2026Q2 2026ACHCAcadia Healthcare$0.33N/AN/AN/A$848.09 millionN/A5/12/2026Q1 2026NGNENeurogene-$1.2963-$1.39-$0.0938-$1.39N/AN/A5/6/2026Q1 2026TSHATaysha Gene Therapies-$0.10-$0.12-$0.02-$0.12$0.76 millionN/A4/29/2026Q1 2026ACHCAcadia Healthcare$0.28$0.37+$0.09$0.05$823.51 million$828.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACHCAcadia HealthcareN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHCAcadia Healthcare1.271.711.71NGNENeurogeneN/A13.0813.08TSHATaysha Gene Therapies0.2314.0414.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHCAcadia HealthcareN/ANGNENeurogene52.37%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipACHCAcadia Healthcare1.20%NGNENeurogene11.68%TSHATaysha Gene Therapies3.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHCAcadia Healthcare25,00091.97 million90.86 millionOptionableNGNENeurogene9015.80 million13.96 millionOptionableTSHATaysha Gene Therapies180287.36 million277.36 millionOptionableACHC, NGNE, and TSHA HeadlinesRecent News About These CompaniesTaysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest InJuly 15 at 6:09 PM | finance.yahoo.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Up 7.4% - Still a Buy?July 14, 2026 | marketbeat.comInsider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of StockJuly 11, 2026 | insidertrades.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of StockJuly 10, 2026 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.3% - What's Next?July 10, 2026 | marketbeat.comTaysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label PotentialJune 30, 2026 | seekingalpha.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 25, 2026 | finanznachrichten.deTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical ...June 25, 2026 | enidnews.comETaysha Gene Therapies Announces Major Equity Financing DealJune 25, 2026 | tipranks.comTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingJune 25, 2026 | globenewswire.comTaysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200MJune 25, 2026 | msn.comTaysha Gene Therapies Prices $200 Million Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | quiverquant.comQTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 24, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and AbbVie (ABBV)June 23, 2026 | theglobeandmail.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - SlideshowJune 23, 2026 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome TranscriptJune 22, 2026 | seekingalpha.comTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 ...June 22, 2026 | markets.businessinsider.comTaysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)June 22, 2026 | msn.comTaysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year RecoveryJune 13, 2026 | finance.yahoo.comIs Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHC, NGNE, and TSHA Company DescriptionsAcadia Healthcare NASDAQ:ACHC$34.50 +0.89 (+2.65%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$34.62 +0.12 (+0.33%) As of 07/17/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.Neurogene NASDAQ:NGNE$37.31 +0.81 (+2.22%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$37.38 +0.07 (+0.20%) As of 07/17/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Taysha Gene Therapies NASDAQ:TSHA$5.96 -0.01 (-0.17%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$6.12 +0.16 (+2.65%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
